Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Cho

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Aging Cell|November 28, 2024
The Ercc1<sup>-/Δ</sup> mouse model of XFE progeroid syndrome undergoes accelerated retinal degenerationAkilavalli Narasimhan, Seok Hong Min, Laura L Johnson, et al.
Science Translational Medicine|September 24, 2025
Retinal polyunsaturated fatty acid supplementation reverses aging-related vision decline in miceFangyuan Gao, Emily Tom, Cezary Rydz, et al.
Alzheimer'S Research & Therapy|September 21, 2018
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)Stephen Salloway, Lee A Honigberg, William Cho, et al.
Applied Neuropsychology. Adult|June 25, 2019
Normative data stratified by age and education for a Spanish neuropsychological test battery: Results from the Colombian Alzheimer's prevention initiative registryValeria L Torres, Clara Vila-Castelar, Yamile Bocanegra, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical <i>PSEN1</i> E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohortPierre N Tariot, Francisco Lopera, Jessica B Langbaum, et al.
Annals of Clinical and Translational Neurology|January 11, 2022
A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALSJonathan S Katz, Jeffrey D Rothstein, Merit E Cudkowicz, et al.
Neuroimage|December 15, 2012
Evaluation of [¹⁸F]MK-0911, a positron emission tomography (PET) tracer for opioid receptor-like 1 (ORL1), in rhesus monkey and humanEric D Hostetler, Sandra Sanabria-Bohórquez, Waisi Eng, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 18, 2020
Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia TrialSilvia Rios-Romenets, Francisco Lopera, Kaycee M Sink, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|November 12, 2025
30<sup>th</sup> Anniversary of Phytomedicine: Looking Back and ForthThomas Efferth, Susana Zacchino, Milen Georgiev, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Aging Cell|November 28, 2024
The Ercc1<sup>-/Δ</sup> mouse model of XFE progeroid syndrome undergoes accelerated retinal degenerationAkilavalli Narasimhan, Seok Hong Min, Laura L Johnson, et al.
Science Translational Medicine|September 24, 2025
Retinal polyunsaturated fatty acid supplementation reverses aging-related vision decline in miceFangyuan Gao, Emily Tom, Cezary Rydz, et al.
Alzheimer'S Research & Therapy|September 21, 2018
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)Stephen Salloway, Lee A Honigberg, William Cho, et al.
Applied Neuropsychology. Adult|June 25, 2019
Normative data stratified by age and education for a Spanish neuropsychological test battery: Results from the Colombian Alzheimer's prevention initiative registryValeria L Torres, Clara Vila-Castelar, Yamile Bocanegra, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical <i>PSEN1</i> E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohortPierre N Tariot, Francisco Lopera, Jessica B Langbaum, et al.
Annals of Clinical and Translational Neurology|January 11, 2022
A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALSJonathan S Katz, Jeffrey D Rothstein, Merit E Cudkowicz, et al.
Neuroimage|December 15, 2012
Evaluation of [¹⁸F]MK-0911, a positron emission tomography (PET) tracer for opioid receptor-like 1 (ORL1), in rhesus monkey and humanEric D Hostetler, Sandra Sanabria-Bohórquez, Waisi Eng, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 18, 2020
Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia TrialSilvia Rios-Romenets, Francisco Lopera, Kaycee M Sink, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|November 12, 2025
30<sup>th</sup> Anniversary of Phytomedicine: Looking Back and ForthThomas Efferth, Susana Zacchino, Milen Georgiev, et al.
Pageof 4